We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen to Buy ChemoCentryx, Gaining First-in-Class Inflammation Drug
Amgen to Buy ChemoCentryx, Gaining First-in-Class Inflammation Drug
Amgen announced that it is acquiring ChemoCentryx, a developer of oral therapies to treat autoimmune diseases, inflammatory disorders and cancer, for approximately $3.7 billion.